Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Study identifier:D419CC00026

ClinicalTrials.gov identifier:NCT05667064

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Specific use-results study of IMJUDO Intravenous Infusion 25 mg, 300 mg / IMFINZI Intravenous Infusion 120 mg, 500 mg All Patient Investigation in patients with unresectable hepatocellular carcinoma

Medical condition

Unresectable Hepatocellular Carcinoma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

300

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 10 May 2023
Estimated Primary Completion Date: 31 Dec 2026
Estimated Study Completion Date: 31 Dec 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria